JPMorgan: After Genscript Biotech (01548.HK) placement, share price rises against the market; reiterates "Overweight" rating.

Zhitong Finance APP has learned that JPMorgan released a research report stating that the share price of GenScript Biotech (01548.HK) rose more than 1% against the market last Friday (the 11th), compared with a 1.4% decline in the Hang Seng Healthcare Index on the same day. The bank expects that AIDD order momentum will continue, capacity utilization will remain stable, and delivery cycles will accelerate, and maintains an "Overweight" rating and a target price of HK$41 for GenScript Biotech.